OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally.
Flawless balance sheet and overvalued.
Share Price & News
How has OraSure Technologies's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: OSUR's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: OSUR exceeded the US Medical Equipment industry which returned -5.2% over the past year.
Return vs Market: OSUR exceeded the US Market which returned -13.3% over the past year.
Price Volatility Vs. Market
How volatile is OraSure Technologies's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StWhat Is OraSure Technologies's (NASDAQ:OSUR) P/E Ratio After Its Share Price Rocketed?
2 weeks ago | Simply Wall StDid You Manage To Avoid OraSure Technologies's (NASDAQ:OSUR) 47% Share Price Drop?
4 weeks ago | Simply Wall StIs There Now An Opportunity In OraSure Technologies, Inc. (NASDAQ:OSUR)?
Is OraSure Technologies undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: OSUR ($11.11) is trading above our estimate of fair value ($0.35)
Significantly Below Fair Value: OSUR is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: OSUR is poor value based on its PE Ratio (41.1x) compared to the Medical Equipment industry average (37.5x).
PE vs Market: OSUR is poor value based on its PE Ratio (41.1x) compared to the US market (12.5x).
Price to Earnings Growth Ratio
PEG Ratio: OSUR's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: OSUR is good value based on its PB Ratio (2.2x) compared to the US Medical Equipment industry average (2.9x).
How is OraSure Technologies forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OSUR's earnings are forecast to decline over the next 3 years (-139.7% per year).
Earnings vs Market: OSUR's earnings are forecast to decline over the next 3 years (-139.7% per year).
High Growth Earnings: OSUR's earnings are forecast to decline over the next 3 years.
Revenue vs Market: OSUR's revenue (1.8% per year) is forecast to grow slower than the US market (7% per year).
High Growth Revenue: OSUR's revenue (1.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: OSUR is forecast to be unprofitable in 3 years.
How has OraSure Technologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OSUR has a large one-off gain of $9.0M impacting its December 31 2019 financial results.
Growing Profit Margin: OSUR's current net profit margins (10.8%) are lower than last year (11.2%).
Past Earnings Growth Analysis
Earnings Trend: OSUR has become profitable over the past 5 years, growing earnings by 26.5% per year.
Accelerating Growth: OSUR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: OSUR had negative earnings growth (-18.3%) over the past year, making it difficult to compare to the Medical Equipment industry average (1%).
Return on Equity
High ROE: OSUR's Return on Equity (5.4%) is considered low.
How is OraSure Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: OSUR's short term assets ($224.6M) exceed its short term liabilities ($32.7M).
Long Term Liabilities: OSUR's short term assets ($224.6M) exceed its long term liabilities ($9.4M).
Debt to Equity History and Analysis
Debt Level: OSUR is debt free.
Reducing Debt: OSUR has not had any debt for past 5 years.
Debt Coverage: OSUR has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: OSUR has no debt, therefore coverage of interest payments is not a concern.
What is OraSure Technologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OSUR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate OSUR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OSUR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OSUR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OSUR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Steve Tang (58yo)
Dr. Stephen S. Tang, also known as Steve, Ph.D. has been President and Chief Executive Officer at OraSure Technologies, Incorporation since April 01, 2018. Dr. Tang has been Chief Executive Officer and Pre ...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD2.10M) is below average for companies of similar size in the US market ($USD3.25M).
Compensation vs Earnings: Steve's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
|CFO & Principal Accounting Officer||1.83yrs||US$1.05m||0.15% $1.0m|
|Senior VP||19.42yrs||US$973.46k||0.22% $1.5m|
|Executive VP & Business Unit Leader of Infectious Disease||3.25yrs||US$1.06m||0.37% $2.5m|
|Vice President of Corporate Communications||1.67yrs||no data||no data|
|Executive VP & Business Unit Leader of Molecular Solutions||7.42yrs||no data||0.17% $1.2m|
|Senior Vice President of Business Development||2yrs||no data||no data|
|VP of Finance||1.5yrs||no data||0.024% $165.1k|
Experienced Management: OSUR's management team is considered experienced (2 years average tenure).
|Independent Director||14.25yrs||US$168.99k||0.10% $693.7k|
|Independent Director||4.08yrs||US$157.24k||0.049% $338.8k|
|Independent Director||16.92yrs||US$169.74k||0.034% $233.7k|
|Independent Chairman of the Board||2yrs||US$506.36k||0.10% $695.9k|
|Director||0.67yr||no data||0.022% $149.2k|
|Independent Director||2.83yrs||US$157.24k||0.038% $261.3k|
|Independent Director||2.17yrs||US$562.31k||0.027% $187.4k|
Experienced Board: OSUR's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
OraSure Technologies, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: OraSure Technologies, Inc.
- Ticker: OSUR
- Exchange: NasdaqGS
- Founded: 2000
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$688.850m
- Shares outstanding: 62.00m
- Website: https://www.orasure.com
Number of Employees
- OraSure Technologies, Inc.
- 220 East First Street
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|OSUR||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Nov 1986|
|EP3||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Nov 1986|
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Its principal products include OraQuick ADVANCE HIV-1/2, OraQuick HIV–1/2, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV, OraQuick Ebola, OraQuick Zika, OraSure QuickFlu Rapid Flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect DX, ORAcollect DNA, Performagene, OMNIgene GUT, OMNIgene SPUTUM, OMNIgene VAGINAL, OMNIgene ORAL, GenoFIND, Hemagene, PrepIT, Intercept, MICRO-PLATE DOA assays, Intercept i2, homogeneous DOA assays, and professional and over-the-counter cryosurgical systems. In addition, the company manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. Further, it provides medical devices for the removal of benign skin lesions by cryosurgery or freezing; immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. OraSure Technologies, Inc. was founded in 2000 and is based in Bethlehem, Pennsylvania.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/07 02:05|
|End of Day Share Price||2020/04/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.